Luis Guirao

Dr. Luis Guirao


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2025 in Toxins
Verified
Journal Article
Open access
CCCarlos Cordero
Carlos Cordero
Irene De-TorresIrene De-Torres
Irene De-Torres
FJFormigo-Couceiro Jacobo
Formigo-Couceiro Jacobo
LGLuis Guirao
Luis Guirao
MRMª Dolores Romero-Torres
Mª Dolores Romero-Torres
AMAntonio Mena-Rodriguez
Antonio Mena-Rodriguez
The study aimed to identify expert opinions and obtain recommendations on the management of post-stroke hemiplegic shoulder pain (HSP) and treatment with botulinum toxin A (BoNT-A). A multicenter Delphi study was conducted using an online survey designed by a committee of experts with at least 10 years of experience in post-stroke HSP management with BoNT-A in Spain. Forty-seven panelists (specialists with at least 5 years of experience in post-stroke HSP management with BoNT-A) rated their level of agreement in two rounds based on acceptance by ≥66.7% of them. In round 1, 245 statements on three dimensions were evaluated (diagnosis, treatment, and follow-up of the HSP patients treated with BoNT-A). A total of 159 statements (70.9%) were finally accepted after round 2. Experts recommended BoNT-A as soon as spasticity affects daily activities. They considered ultrasound as the preferred guided technique. Experts recommended regular assessments using validated scales and patient-reported outcomes to evaluate treatment goals and safety. In case of lack of response, experts suggested increasing the dose or number of treated muscles or considering alternative treatments. These consensus-based recommendations offer clinicians an approach to the management of post-stroke HSP with BoNT-A, supporting informed decision making.

22 January 2026 in Toxins
Verified
Journal Article
Open access
PDF file
Helena Bascuñana-AmbrósHelena Bascuñana-Ambrós
Helena Bascuñana-Ambrós
JFJacobo Formigo-Couceiro
Jacobo Formigo-Couceiro
JCJosé Maria Climent-Barberá
José Maria Climent-Barberá
LGLuis Guirao
Luis Guirao
Michelle Cavariani Catta-PretaMichelle Cavariani Catta-Preta
Michelle Cavariani Catta-Preta
JFJosep Monguet Fierro
Josep Monguet Fierro
Background: Spasticity, which occurs with certain neurological conditions, substantially affects quality of life, function, and social participation. Despite widespread botulinum toxin use, variability persists in patient information, access to specialized rehabilitation, and follow-up models. Methods: This two-phase Delphi-Dialogue Patients–Professionals study (DDPP), promoted by SERMEF, integrated perspectives from 77 patients and 141 rehabilitation professionals. Phase 1 used parallel surveys to assess satisfaction, perceived effectiveness of botulinum toxin, communication preferences, and rehabilitation follow-up. Phase 2 applied Real-Time Delphi with 38 experts to generate consensus recommendations to improve spasticity management. Results: Patients and professionals agreed on botulinum toxin benefits, the importance of ongoing rehabilitation, and the value of hybrid (in-person/remote) follow-up. Key gaps concerned access to Physical Medicine and Rehabilitation services, clarity and timing of information, and shared goal setting. Experts translated these misalignments into 10 prioritized recommendations, with highest feasibility for actions standardizing access pathways, optimizing botulinum toxin use, reinforcing structured education, and consolidating hybrid rehabilitation models. Conclusions: The DDPP approach offers a reproducible framework to align stakeholder perspectives by converting quantified divergence into consensus-based innovation priorities. Implementing the recommendations—particularly those strengthening communication, education, and hybrid pathways regarding botulinum toxin treatment—may support more accessible, personalized, patient-centered spasticity care.

28 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Helena Bascuñana-AmbrósHelena Bascuñana-Ambrós
Helena Bascuñana-Ambrós
JFJacobo Formigo-Couceiro
Jacobo Formigo-Couceiro
JCJosé Maria Climent-Barberá
José Maria Climent-Barberá
LGLuis Guirao
Luis Guirao
Michelle Cavariani Catta-PretaMichelle Cavariani Catta-Preta
Michelle Cavariani Catta-Preta
JFJosep Monguet Fierro
Josep Monguet Fierro
Background: Spasticity significantly impacts quality of life, function, and social participation in individuals with neurological conditions. Despite the widespread use of botulinum toxin, variability persists in patient information, access to specialized rehabilitation, and follow-up models. Methods: This two-phase Delphi-Dialogue Patients-Professionals study (DDPP), promoted by the Spanish Society of Physical Medicine and Rehabilitation (SERMEF), integrated perspectives from 77 patients and 141 rehabilitation professionals. In Phase 1, parallel surveys assessed satisfaction, perceived effectiveness of botulinum toxin, communication preferences, and rehabilitation follow-up. In Phase 2, a Real-Time Delphi process with 38 experts generated consensus recommendations for improving spasticity management. Results: Patients and professionals broadly agreed on the benefits of botulinum toxin, the importance of ongoing rehabilitation, and the value of hybrid (in-person/remote) follow-up, but relevant gaps emerged regarding access to Physical Medicine and Rehabilitation services, clarity and timing of information, and shared goal setting. The expert panel converted these misalignments into a prioritized set of ten recommendations, with the highest feasibility assigned to actions that standardize access pathways, optimize botulinum toxin use, reinforce structured education, and consolidate hybrid rehabilitation models. Conclusions: The DDPP methodology provides a reproducible framework for aligning patient and professional perspectives in spasticity care by transforming quantified divergence into consensus-based innovation priorities. Implementing the agreed recommendations—especially those that reinforce communication, structured education, and hybrid rehabilitation pathways around botulinum toxin treatment—may help spasticity services evolve toward a more accessible, personalized, and patient-centered model.